EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

B Cell dysfunction in tumor-draining lymph nodes predicts relapse in oral squamous cell carcinoma

Vilma Liljeström, Pedro Farrajota Neves da Silva, Rusana Bark, Alexandra Elliot, Linda Marklund, Gregori Margolin, Susanna Kumlien Georén, Lars-Olaf Cardell, Krzysztof Piersiala

Cancer Immunology, Immunotherapy · 12.11.2025 · 74 (12)

DOI: 10.1007/s00262-025-04231-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 12.11.2025. Verfasst von Vilma Liljeström und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of ENT Diseases, Department of Clinical Sciences, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Mouth Neoplasms, Lymph Nodes, Neoplasm Recurrence, Local, Carcinoma, Squamous Cell. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ALF Region Stockholm, Cancerfonden, Radiumhemmets Forskningsfonder.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oral squamous cell carcinoma (OSCC) presents a persistent clinical challenge, with high recurrence rates and limited improvements in survival despite therapeutic advances. Tumor-draining lymph nodes (TDLNs) are key immunological sites where anti-tumor responses are orchestrated, yet the prognostic relevance of B cell phenotypes in TDLNs remains underexplored. TDLNs from 49 OSCC patients treated at Karolinska University Hospital were prospectively analyzed. Single-cell suspensions were examined using multicolor flow cytometry to characterize B cell subsets (naïve, memory, plasma cells) and expression of immunoregulatory markers (CD11c, CD24, CXCR5, CD73, HLA-DR, PD-L1). B cell profiles were correlated with clinical outcomes, including disease-free survival (DFS) and overall survival (OS). Disease-free patients exhibited a distinct B cell profile marked by a higher proportion of naïve B cells, strong CXCR5 and CD11c expression, and increased plasma cell differentiation. Recurrence was associated with elevated CD24, CD73, and HLA-DR expression, markers linked to immunoregulatory or dysfunctional B cell states. Interestingly, high PD-L1 expression on memory B cells correlated with improved prognosis, suggesting a context-dependent immune function. In line with these observations, multivariate analysis confirmed HLA-DR expression, together with nodal status, as independent prognostic factors for survival in OSCC. B cell phenotypes in OSCC TDLNs are strongly associated with patient outcomes. A microenvironment enriched in naïve and functionally active B cells supports durable tumor control, whereas regulatory/exhausted phenotypes are linked to recurrence. These findings position B cell markers as promising prognostic indicators and therapeutic targets in OSCC, warranting validation in larger cohorts and functional studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mouth NeoplasmsLymph NodesNeoplasm Recurrence, LocalCarcinoma, Squamous CellB-LymphocytesHumansMaleFemaleMiddle AgedPrognosisAgedAdultBiomarkers, TumorAged, 80 and overProspective Studies

Stichwörter der Autor:innen

B cellsFlow cytometryOral squamous cell carcinomaPrognosisRecurrenceTumor-draining lymph nodes

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Division of ENT Diseases, Department of Clinical Sciences, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
  • Department of Pathology and Cancer Diagnostics, Karolinska University Hospital, Stockholm, Sweden.
  • Medical Unit Head Neck, Lung and Skin Cancer, Karolinska University Hospital, Stockholm, Sweden.
  • Department of Surgical Sciences, Section of Otolaryngology and Head and Neck Surgery, Uppsala University, Uppsala, Sweden.
  • Department of Otorhinolaryngology, Karolinska University Hospital, Stockholm, Sweden.
  • Division of ENT Diseases, Department of Clinical Sciences, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden. krzysztof.piersiala@ki.se.

Förderung

  • ALF Region Stockholm
  • Cancerfonden
  • Radiumhemmets Forskningsfonder
  • Vetenskapsrådet
  • Center for Innovative Medicine
  • Karolinska Institute

Zitieren

APA

Liljeström, V., Farrajota Neves da Silva, P., Bark, R., Elliot, A., Marklund, L., Margolin, G., Kumlien Georén, S., Cardell, L. O., & Piersiala, K. (2025). B Cell dysfunction in tumor-draining lymph nodes predicts relapse in oral squamous cell carcinoma. Cancer Immunology, Immunotherapy, 74(12). https://doi.org/10.1007/s00262-025-04231-9

Vancouver

Liljeström V, Farrajota Neves da Silva P, Bark R, Elliot A, Marklund L, Margolin G, et al. B Cell dysfunction in tumor-draining lymph nodes predicts relapse in oral squamous cell carcinoma. Cancer Immunology, Immunotherapy. 2025;74(12). doi:10.1007/s00262-025-04231-9

BibTeX
@article{Liljestrm2025,
  author = {Liljeström, Vilma and Farrajota Neves da Silva, Pedro and Bark, Rusana and Elliot, Alexandra and Marklund, Linda and Margolin, Gregori and Kumlien Georén, Susanna and Cardell, Lars-Olaf and Piersiala, Krzysztof},
  title = {B Cell dysfunction in tumor-draining lymph nodes predicts relapse in oral squamous cell carcinoma},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2025},
  volume = {74},
  number = {12},
  doi = {10.1007/s00262-025-04231-9}
}
Kostenlos starten →